Dr Charles Shepherd summarises the key points to emerge from the NICE Stakeholders Engagement Workshop that took place on Tuesday 16th January 2018.

A new film sheds light on a condition that is largely ignored. Nathalie Wright reports on the struggles patients face to be taken seriously by doctors.

A recent scientific trial has led to acrimonious debates over chronic fatigue syndrome, aka ME, and boosted interest in a secretive therapy that some call a “cult” and others call a “miracle”.

The following article appeared in The Hippocratic Post, and was written by Rebecca Wallersteiner, on 25th November, 2017. It features comment from Sarah Staples, and Dr Charles Shepherd, from the ME Association.

“Despite the headline negative finding, we believe that this trial will still provide useful insights and contribute to a better understanding of M.E., and we also have the results from the Cyclophosphamide clinical trial to look forward to. We are very pleased that this knowledgeable, and valued, research team will continue with their work, trying to find answers to the M.E. puzzle.”

  Published in the Journal Fatigue: Biomedicine, Health & Behaviour,

  This article appeared in the New Scientist on November

  Last Saturday saw Jennifer Brea and Dr Charles Shepherd

  By Dr Charles Shepherd, Hon Medical Adviser to the

We wrote to Sir Andrew Dillon last Friday, with a covering letter (below) and enclosed the final petition – supported by 13,593 people.

The suspected neurological conditions guideline specifically refers to M.E./CFS as a ‘functional’ disorder, which it defines as being ‘driven by emotion’ that, ‘may mimic physical disease’.

  Following the stakeholder consultation, NICE have this morning announced